keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28548372/initial-multicentre-experience-of-68-gallium-psma-pet-ct-guided-robot-assisted-salvage-lymphadenectomy-acceptable-safety-profile-but-oncological-benefit-appears-limited
#1
Amila Siriwardana, James Thompson, Pim J van Leeuwen, Shaela Doig, Anton Kalsbeek, Louise Emmett, Warick Delprado, David Wong, Hemamali Samaratunga, Anne-Maree Haynes, Geoff Coughlin, Phillip Stricker
OBJECTIVES: To evaluate the safety and short-term oncological outcomes for (68) Ga-PSMA PET/CT directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for (68) Ga-PSMA PET/CT detected oligometastatic nodal recurrence. RASND was performed by targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease...
May 26, 2017: BJU International
https://www.readbyqxmd.com/read/28546332/establishing-177-lu-psma-617-radioligand-therapy-in-a-syngeneic-model-of-murine-prostate-cancer
#2
Wolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, Katharina Lückerath, Liu Wei, Woosuk Kim, Soumya Poddar, Jonathan Said, Caius G Radu, Matthias Eiber, Johannes Czernin, Roger Slavik, Ken Herrmann
Clinical (177)Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced stage prostate cancer. However, to the best of our knowledge murine models to study the biological effects of various activity levels have not been established. AIM: To optimize specific and total activity for (177)Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer. Methods: 0.1x106 murine reconstituted, oncogene-driven prostate cancer cells (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected into the left flank of C57Bl6 immunocompetent mice...
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28546330/exploring-new-multimodal-quantitative-imaging-indices-for-the-assessment-of-osseous-tumour-burden-in-prostate-cancer-using-68-ga-psma-pet-ct
#3
Marie Bieth, Markus Krönke, Robert Tauber, Marielena Dahlbender, Margitta Retz, Stephan G Nekolla, Bjoern Menze, Tobias Maurer, Matthias Eiber, Markus Schwaiger
Positron-emission-tomography (PET) combined with computed-tomography (CT) and prostate-specific-membrane-antigen (PSMA) ligands has gained significant interest for staging prostate cancer (PC). In this study, we propose two multimodal quantitative indices as imaging biomarker for the assessment of osseous tumour burden using (68)Ga-PSMA-PET/CT and present preliminary clinical data. We define two Bone-PET-Indices (BPI) that incorporate anatomical information from CT and functional information from (68)Ga-PSMA-PET: BPIVOL is the percental bone volume affected by tumour...
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28540419/therapy-assessment-in-prostate-cancer-using-choline-and-psma-pet-ct
#4
REVIEW
Francesco Ceci, Ken Herrmann, Boris Hadaschik, Paolo Castellucci, Stefano Fanti
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients...
May 25, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28536833/development-of-standardized-image-interpretation-for-68ga-psma-pet-ct-to-detect-prostate-cancer-recurrent-lesions
#5
Stefano Fanti, Silvia Minozzi, Joshua James Morigi, Frederik Giesel, Francesco Ceci, Christian Uprimny, Michael S Hofman, Matthias Eiber, Sarah Schwarzenbock, Paolo Castellucci, Cristina Bellisario, Stéphane Chauvie, Fabrizio Bergesio, Louise Emmett, Uwe Haberkorn, Irene Virgolini, Markus Schwaiger, Rodney J Hicks, Bernd J Krause, Arturo Chiti
METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence...
May 23, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28534214/repeatability-of-68-ga-dkfz11-psma-pet-scans-for-detecting-prostate-specific-membrane-antigen-positive-prostate-cancer
#6
Joseph R Osborne, Teja M Kalidindi, Blesida J Punzalan, Kishore Gangangari, Daniel E Spratt, Wolfgang A Weber, Steven M Larson, Naga Vara Kishore Pillarsetty
PURPOSE: We studied the effect of varying specific activity of [(68)Ga]DKFZ-PSMA11 ([(68)Ga]DP11) on repeated imaging of prostate-specific membrane antigen-positive (PSMA+) xenograft tumors. PROCEDURES: Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA-) bilateral flank tumors were assessed to study intra- and inter-day repeatability of [(68)Ga]DP11 imaging in mice administered [(68)Ga]DP11 or [(67)Ga]DP11 (as a dilution tracer) using imaging and biodistribution studies...
May 22, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28533936/synthesis-and-evaluation-of-64-cu-psma-617-targeted-for-prostate-specific-membrane-antigen-in-prostate-cancer
#7
Can Cui, Masayuki Hanyu, Akiko Hatori, Yiding Zhang, Lin Xie, Tomoya Ohya, Masami Fukada, Hisashi Suzuki, Kotaro Nagatsu, Cuiping Jiang, Rui Luo, Guoqiang Shao, Mingrong Zhang, Feng Wang
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 ((64)Cu), to evaluate the metabolism, biodistribution, and potential of [(64)Cu]PSMA-617 for PET imaging of prostate cancer. [(64)Cu]PSMA-617 was synthesized by heating PSMA-617 with [(64)Cu]CuCl2 in buffer solution at 90°C for 5 min. In vitro uptake was determined in two cell lines of prostate cancer. In vivo regional distributions were determined in normal and tumor-bearing mice. High radiolabeling efficiency of (64)Cu for PSMA-617 yielded [(64)Cu]PSMA-617 with >99% radiochemical purity...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28533806/second-salvage-high-dose-rate-brachytherapy-for-radiorecurrent-prostate-cancer
#8
Metha Maenhout, Marco van Vulpen, Marinus Moerland, Max Peters, Richard Meijer, Maurice van den Bosch, Paul Nguyen, Steven Frank, Jochem van der Voort van Zyp
PURPOSE: Salvage treatments for localized radiorecurrent prostate cancer can be performed safely when a focal and image guided approach is used. Due to the low toxicity, the opportunity exists to investigate a second salvage treatment when a second locally recurrent prostate cancer occurs. Here, we describe a second salvage treatment procedure of 4 patients. MATERIAL AND METHODS: Four patients with a pathologically proven second local recurrence were treated in an outpatient magnetic resonance imaging (MRI)-guided setting with a single fraction of 19 Gy focal high-dose-rate brachytherapy (HDR-BT)...
April 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28533654/psma-expression-in-multinodular-thyroid-neoplasm-on-simultaneous-ga-68-psma-pet-mri
#9
Amarnath Jena, Shuaib Zaidi, Vikas Kashyap, Abhishek Jha, Sangeeta Taneja
PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI. The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted USG-guided FNAC which revealed Hurthle cell neoplasm. Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533641/image-findings-of-a-rare-case-of-neuroendocrine-tumor-metastatic-to-orbital-extraocular-muscle-in-gallium-68-dotanoc-positron-emission-tomography-computed-tomography-and-therapy-with-lutetium-177-dotatate
#10
Koramadai Karuppusamy Kamaleshwaran, Jephy Joseph, Indra Upadhya, Ajit Sugunan Shinto
Metastatic tumor is one of several etiologies of space-occupying masses in the orbit that accounts for 1-13% of all orbital masses. In the adult patient population, breast cancer is the most common tumor to metastasize to the orbit, followed by metastasis from the lung, prostate, and gastrointestinal tract. Carcinoid tumors are rare neuroendocrine neoplasms derived from enterochromaffin cells, which are found primarily in the gastrointestinal tract and bronchial tree. Liver metastases are the classic presentation of distant disease...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533638/clinical-utility-of-gallium-68-psma-pet-ct-scan-for-prostate-cancer
#11
Kumaraswamy G Kallur, Prashanth G Ramachandra, Krishnappa Rajkumar, Shivakumar S Swamy, Indiresh Desai, Raghavendra M Rao, Shekhar Gowda Patil, P S Sridhar, Nagaraj Madhusudhan, Raghunath S Krishnappa, Veerendra Bhadrasetty, Hemantha M Kumara, S D Santhosh, Basavalingaiah S Ajaikumar
BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28529650/diagnostic-accuracy-of-ga-68-hbed-cc-psma-ligand-pet-ct-before-salvage-lymph-node-dissection-for-recurrent-prostate-cancer
#12
Cordula A Jilg, Vanessa Drendel, H Christian Rischke, Teresa Beck, Werner Vach, Kathrin Schaal, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer
Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND). Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa...
2017: Theranostics
https://www.readbyqxmd.com/read/28526417/imaging-of-a-pelvic-textiloma-using-18-f-fdg-pet-ct-in-a-patient-with-a-history-of-prostate-cancer-a-case-report-and-review-of-the-literature
#13
Romain Schollhammer, Henri De Clermont-Gallerande, Philippe Fernandez, Marie Meyer
No abstract text is available yet for this article.
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28525451/metastases-from-colorectal-cancer-avid-on-68ga-psma-pet-ct
#14
Lise Hangaard, Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Kirsten Bouchelouche
Ga-PSMA PET/CT is currently used for detection of prostate cancer including metastases, even at low prostate-specific antigen values. A grown number of reports have shown increased uptake of PSMA in neovessels of nonprostatic malignancies including lung cancer, and recently a case report has demonstrated increased PSMA uptake in colorectal adenocarcinoma. In this case report, we demonstrate increased Ga-PMSA uptake on PET/CT in metastases from previously treated colon adenocarcinoma, and it illustrates the importance of histology of suspicious lesions on Ga-PSMA PET/CT...
May 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28525448/18f-fluorocholine-pet-ct-complementing-the-role-of-dynamic-contrast-enhanced-mri-for-providing-comprehensive-diagnostic-workup-in-prostate-cancer-patients-with-suspected-relapse-following-radical-prostatectomy
#15
Shelvin Kumar Vadi, Baljinder Singh, Rajender K Basher, Ankit Watts, Ashwani K Sood, Anupam Lal, Nandita Kakkar, S K Singh
PURPOSE: The aim of this study was to compare the diagnostic performance of F-fluorocholine (FCH) PET/CT and dynamic contrast-enhanced MRI (DCE-MRI) of pelvis in restaging prostate cancer (PC) patients with biochemical recurrence (BCR) following radical prostatectomy (RP). METHODS: Twenty PC patients who had undergone RP and had BCR were recruited in this study. All the patients underwent whole-body FCH PET/CT and DCE-MRI of the pelvis. An overall pattern of recurrent disease was analyzed, and diagnostic accuracy for the detection of pelvic disease recurrence by the 2 modalities was evaluated by taking histopathologic analysis as the criterion standard...
May 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28524118/novel-radiolabeled-bisphosphonates-for-pet-diagnosis-and-endoradiotherapy-of-bone-metastases
#16
REVIEW
Nina Pfannkuchen, Marian Meckel, Ralf Bergmann, Michael Bachmann, Chandrasekhar Bal, Mike Sathekge, Wolfgang Mohnike, Richard P Baum, Frank Rösch
Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of (99m)Tc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, owing to the (68)Ge/(68)Ga generator, an analog to the established (99m)Tc generator exists. Complexation of Ga(III) requires the use of chelators...
May 18, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28523180/primary-atypical-carcinoid-tumor-of-the-mediastinum-a-very-rare-finding
#17
Luigi Ventura, Letizia Gnetti, Enrico Maria Silini, Guido Rindi, Paolo Carbognani, Michele Rusca, Luca Ampollini
Primary neuroendocrine tumors (NETs) of the mediastinum are very rare. Prognosis is usually poor despite treatment options. We present the case of a primary atypical carcinoid tumor of the mediastinum successfully treated by multimodal approach. A 50-year-old man presented for asthenia, dyspnea, and substernal sense of weight for two weeks. A chest-CT scan revealed a tumor mass of 107×55×95 mm(3) localized in the anterosuperior mediastinum compressing both brachiocephalic veins, the superior vena cava, the pericardium, and lungs...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28522741/impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#18
Thomas A Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L Greene, Matthew Cooperberg, Felix Feng, Albert Chang, Charles J Ryan, Eric J Small, Peter R Carroll
Purpose: The purpose of this prospective study was to estimate the effect of (68)Ga-prostate specific membrane antigen (PSMA)-11 PET on intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and post-imaging surveys were filled out by referring providers in patients with biochemical recurrence who were imaged using (68)Ga-PSMA-11 PET. Inclusion criteria for this study required a PSA doubling time of less than 12 months after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate)...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522740/initial-experience-with-volumetric-68-ga-psma-i-t-pet-ct-for-assessment-of-whole-body-tumor-burden-as-a-quantitative-imaging-biomarker-in-patients-with-prostate-cancer
#19
Sebastian Schmuck, Christoph A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether prostate specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) may be applied to provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden. Methods: 101 patients who underwent a (68)Ga-PSMA I&T PET/CT because of increasing prostate specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analysis...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522176/re-diagnostic-accuracy-of-ga-68-hbed-cc-psma-ligand-pet-ct-before-salvage-lymph-node-dissection-for-recurrent-prostate-cancer
#20
Boris Hadaschik, Ken Herrmann
No abstract text is available yet for this article.
May 15, 2017: European Urology
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"